[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Diabetes & Obesity Drug Pipeline to See Further Growth, According to GBI Research Report Now Available at MarketPublishers.com

24 Nov 2016 • by Natalie Aster

LONDON – At present, the diabetes and obesity disease cluster is ruled by the therapeutics indicated for T1DM and T2DM. More than a half of this pipeline is attributable to these indicators (both in terms of quality and quantity products). Products that are indicated for obesity currently cannot boast large presence in the marketplace. There are many these products in the pipeline, though most of they are still in early stages of the development.

The therapy area where diabetes and obesity are combined represents a strong pipeline, making up a large amount of the total metabolic disorders’ therapy area.

Small molecules and biologics form the majority of products, and this reflects the overall trend of the pharmacotherapeutic marketplace.

Presence of the growing pipeline for obesity-indicated products as well as high global media interest shed light on the relevance of this indication along with future potential revenues (globally).

But diabetes-indicated products pose a challenge to the growth of some pharmacotherapeutic products for obesity.  The T2DM pipeline is set to continue showcasing growth in the upcoming years along with an increase of the obesity incidence.

New research report “Diabetes & Obesity Drug Development Pipeline Review, 2016” elaborated by GBI Research offers a comprehensive discussion of the worldwide diabetes and obesity pipeline. The study commences with a detailed overview of the diseases.

It sheds light on the therapeutics development by their stage and companies. The report discusses companies that are most active within this space. The research study focuses on the most important R&D milestones.

Other Marketplaces Explored by GBI Research Comprise:

More new studies by our partner can be found at its page.


The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected]

Analytics & News

Weekly Digest